Learned transcriptomic selection identifies a pediatric-sepsis blood-marker pattern
Source check: Source checked. Not independent scientific confirmation.
Finding: Three learned feature-selection approaches converged on CYSTM1, MMP8 and CD177 in public pediatric blood-expression data. The source reports higher expression and case-control discrimination in a further dataset. This is a retrospective molecular association, including a less-studied CYSTM1 candidate, without established diagnostic specificity, clinical utility or causal treatment relevance.
Technology: Random forest, SVM recursive feature elimination and LASSO logistic feature selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The three learned selectors prioritized a shared measured-expression marker set after broad filtering, enabling the represented candidate-pattern and subsequent source-described case-control comparison. Immune deconvolution or network diagrams alone are not the admission basis.
- Test and result
- The analysis combined GSE26378 and GSE26440, with primary series metadata listing 180 septic-shock and 53 normal-control blood-expression profiles in total. Differential/module filtering preceded RF, SVM-RFE and tenfold-tuned LASSO selection. Their intersection identified CYSTM1, MMP8 and CD177. The paper reports increased expression and discrimination in GSE13904, a separately indexed pediatric inflammatory-spectrum dataset.
- Limitation / still unknown
- Distinct series/sample identifiers do not prove independent people. GSE13904 includes inflammatory-response, sepsis and septic-shock samples; the exact analytic subset and repeated-person separation were not independently reconstructed. Feature filtering used clinical labels before selection, and healthy-control contrasts do not establish real-world diagnostic specificity. Source prose twice refers to rheumatoid arthritis despite the sepsis analysis; no RA result is adopted. MMP8/CD177 links to sepsis were already known, and CYSTM1 remains a candidate association without functional or therapeutic validation. Reported ROC/decision curves do not demonstrate clinical benefit.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10533616/ · https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26378 · https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26440 · https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13904
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Read original computational cohort/filtering/RF/SVM-RFE/LASSO and ROC Methods, candidate/validation-expression Results and stated limits; separately read primary GEO series-level cohort metadata and exact GSM intersections. Patient-level independence and full validation subset were not reconstructed. No operational biological procedures or causal treatment claim. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.